Abstract
Background
Methods
Results
Conclusions
Figures and Tables
Fig. 1
![lmo-4-28-g001](/upload/SynapseData/ArticleImage/0192lmo/lmo-4-28-g001.jpg)
Fig. 2
![lmo-4-28-g002](/upload/SynapseData/ArticleImage/0192lmo/lmo-4-28-g002.jpg)
Fig. 3
![lmo-4-28-g003](/upload/SynapseData/ArticleImage/0192lmo/lmo-4-28-g003.jpg)
Table 2
![lmo-4-28-i002](/upload/SynapseData/ArticleImage/0192lmo/lmo-4-28-i002.jpg)
*Statistical differences in HLC-IgGκ, HLC-IgGκ/IgGλ ratios, and serum immunotyping results between the suspicious electrophoresis group and the definitive monoclonal peak group were evaluated (P<0.05); †Reference range for the HLC assay: IgGκ, 3.84-12.07 g/L; IgGλ, 1.91-6.74 g/L; IgGκ/IgGλ, 1.12-3.21 g/L; IgAκ, 0.57-2.08 g/L; IgAλ, 0.44-2.04 g/L; IgAκ/IgAλ, 0.78-1.94 g/L.
Abbreviations: Ig, immunoglobulin; sFLC assay, serum free light chain assay; FLCκ, free light chain-kappa; FLCλ, free light chain-lambda; HLC assay, heavy/lightchain assay.
Table 3
![lmo-4-28-i003](/upload/SynapseData/ArticleImage/0192lmo/lmo-4-28-i003.jpg)
*In the case of only numerical data without Ig'κ or FLCκ labeling, this indicates that the result of HLC assay or FLC assay was within the reference range (IgGκ/IgGλ, 1.12-3.21, IgAκ/IgAλ, 0.78-1.94; FLCκ/λ, 0.26-1.65); †Described as per the response criteria given by the International Myeloma Working Group.
Abbreviations: SPEP, serum protein electrophoresis; HLC ratios, heavy/lightchain assay κ:λ ratios; sFLC assay, serum free light chain assay; FLCκ, free light chain-kappa; MM, multiple myeloma; SD, stable disease; PR, partial response; VGPR, very good partial response.
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)